Myokines for treating cell proliferative and metabolic diseases and disorders

Patent metadata

Field	Value
Publication number	US-12252522-B2
Application number	US-202318151166-A
Country	US
Kind code	B2
Filing date	Jan 6, 2023
Priority date	May 16, 2019
Publication date	Mar 18, 2025
Grant date	Mar 18, 2025

Abstract

Disclosed are compositions comprising myokines and their methods of preparation and use. The disclosed myokine compositions and methods may comprise myokines having a molecular weight of greater than about 10 kDa such as myostatin and metrnl. The disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders. In particular, the disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders, such as cancer, and metabolic diseases and disorders, such as diabetes, non-alcoholic fatty liver disease, and heart disease.

First claim

We claim:

1. A method for treating colorectal cancer in a subject in need thereof, the method comprising administering to the subject:
(a) an isolated fraction of myokines or a pharmaceutical formulation thereof, wherein the isolated fraction of myokines comprises an effective amount of one or more myokines, and wherein (i) the one or more myokines have a molecular weight greater than about 10 kDa; and/or (ii) the one or more myokines comprise myostatin, metrnl, or both of myostatin and metrnl; and
(b) an effective amount of a platinum-based chemotherapeutic drug or a pharmaceutical formulation thereof.

2. The method of claim 1 , wherein the isolated fraction of myokines comprises myostatin.

3. The method of claim 1 , wherein the isolated fraction of myokines comprises metrnl.

4. The method of claim 1 , wherein the isolated fraction of myokines comprises myostatin and metrnl.

5. The method of claim 1 , further comprising administering an additional chemotherapeutic drug or a pharmaceutical formulation thereof selected from the group consisting of abiraterone, bendamustine, bortezomib, cabazitaxel, chlorambucil, dasatinib, docetaxel, doxorubicin, epirubicin, erlotinib, etoposide, everolimus, gefitinib, idarubicin, imatinib, hydroxyurea, imatinib, lapatinib, leuprorelin, melphalan, methotrexate, mitoxantrone, nilotinib, paclitaxel, pazopanib, pemetrexed, romidepsin, sorafenib, vemurafenib, sunitinib, teniposide, vinblastine, vinorelbine, vincristine, and cyclophosphamide.

6. The method of claim 1 , wherein the platinum-based chemotherapeutic drug is selected from the group consisting of carboplatin, cisplatin, nedaplatin, oxaliplatin, picoplatin, satraplatin, and triplatin.

Assignees

• Univ Northwestern

Inventors

• Roy Hemant K
• Backman Vadim

Classifications

• C07K14/4703

  Inhibitors; Suppressors · CPC title

• A61K31/282 Primary

  Platinum compounds · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K38/18

  Growth factors; Growth regulators · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title